Browsing by Author "Yılmaz, Uğur"
Now showing items 1-6 of 6
-
Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma
Tural, Deniz; Ölmez, Ömer Fatih; Sümbül, Ahmet Taner; Artaç, Mehmet; Özhan, Nail; Akar, Emre; Çakar, Burcu; Köstek, Osman; Ekenel, Meltem; Coşkun, Hasan Şenol; Selçukbiricik, Fatih; Keskin, Özge; Paksoy Türköz, Fatma; Oruç, Kerem; Bayram, Selami; Yılmaz, Uğur; Bilgetekin, İrem; Yıldız, Birol; Şendur, Mehmet Ali Nahit; Erman, Mustafa (Lippincott Williams & Wilkins, 2021)Background: In the current study, we evaluated whether the response first-line chemotherapy could impact atezolizumab benefit in terms of response rate and overall survival in patients with metastatic urothelial carcinoma. ... -
Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experience
Tural, Deniz; Ölmez, Ömer Fatih; Sümbül, Ahmet Taner; Artaç, Mehmet; Özhan, Nail; Akar, Emre; Çakar, Burcu; Köstek, Osman; Paksoy, Nail; Erman, Mustafa; Coşkun, Hasan Şenol; Selçukbiricik, Fatih; Keskin, Özge; Paksoy Türköz, Fatma; Oruç, Kerem; Bayram, Selami; Yılmaz, Uğur; Bilgetekin, İrem; Yıldız, Birol; Kılıçkap, Saadettin (American Society of Clinical Oncology, 2020)... -
Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences
Tural, Deniz; Ölmez, Ömer Fatih; Sümbül, Ahmet Taner; Artaç, Mehmet; Özhan, Nail; Akar, Emre; Çakar, Burcu; Köstek, Osman; Ekenel, Meltem; Erman, Mustafa; Coşkun, Hasan Şenol; Selçukbiricik, Fatih; Keskin, Özge; Paksoy Türköz, Fatma; Oruç, Kerem; Bayram, Selami; Yılmaz, Uğur; Bilgetekin, İrem; Yıldız, Birol; Şendur, Mehmet Ali Nahit; Paksoy, Nail; Dirican, Ahmet; Erdem, Dilek; Selam, Meltem; Tanrıverdi, Özgür; Paydaş, Semra; Urakçı, Zuhat; Atağ, Elif; Güncan, Sabri; Ürün, Yüksel; Alkan, Ali; Kaya, Ali Osman; Tataroğlu Özyükseler, Deniz; Taşkaynatan, Halil; Yıldırım, Mustafa; Sönmez, Müge; Başoğlu, Tuğba; Gündüz, Şeyda; Kılıçkap, Saadettin (Elsevier, 2021)Background: Atezolizumab (ATZ) has demonstrated antitumor activity and manageable safety in previous studies in patients with locally advanced or metastatic platinum resistant urothelial carcinoma. Objective: To compare ... -
Morphological changes in eeg, aquaporin-4, c-fos and the hıppocampus of animal models with temporal lobe epilepsy induced by kainic acid
Taşkıran, Emine; Yılmaz, Uğur; Orhan, Nurcan; Bahçeci, M.; Kaya, Mehmet; Ahıshalı, B.; Küçük, Mutlu; Arıcan, N.; Gürses, Candan (Wiley-Blackwell, 2015)Purpose: Temporal lobe epilepsy (TLE) is the most frequent type of localization relatedfocalepilepsyseeninhumans.Ithasafrequencyrate of 30–35% among all epilepsies, and comprises 70% of intractable epilepsies. With hippocampal ... -
Prognostic factors in patients with metastatic urothelial carcinoma who have been treated with atezolizumab
Tural, Deniz; Ölmez, Ömer Fatih; Sümbül, Ahmet Taner; Özhan, Nail; Akar, Ebru; Çakar, Bilge; Köstek, Osman; Ekenel, Mahmut; Erman, Mustafa; Coşkun, Hasan Şenol; Selçukbiricik, Fatih; Keskin, Özge; Paksoy, Fatma; Oruç, Korkmaz; Bayram, Süleyman Nuri; Yılmaz, Uğur; Bilgetekin, İrem; Yıldız, Birol; Şendur, Mehmet Ali Nahit; Artaç, Macide (Elsevier, 2020)Background: In the current study, we evaluated pretreatment prognostic factors foroverall survival (OS) in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy in the Expanded-Access ... -
Thrombin activatable fibrinolysis inhibitor, tissue factor pathway inhibitor, and prothrombin fragment 1+2 levels in patients with advanced colorectal cancer
Salman, Tarık; Bilici, Ahmet; Arslan, Çağatay; Varol, Umut; Yıldız, İbrahim; Akyol, Murat; Yıldız, Yaşar; Küçükzeybek, Yüksel; Alacacıoğlu, Ahmet; Yılmaz, Uğur (American Society of Clinical Oncology, 2016)...
